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Various mutation on endothelial nitric oxide synthase (eNOs) gene cause reduced production of NO, the 
expansion factor (VEF) and may accelerate the process of atherosclerosis. The study was designed to 
investigate the frequency of T-786C polymorphism of the gene or nucleotide mutation of eNOS gene in 
patients suffering from vascular heart disease (VHD) or coronary artery disease (CAD) in North West of 
Iran. 120 subjects including 60 patients with angiographically diagnosed CAD and 60 age and sex 
matched CAD-free subjects as control were studied. The levels of Nitric oxide in the samples were 
measured with the Griess method. The genotype studies were carried out using allele specific PCR. 
Comparing with the control reduced levels of NO were noticed in the patient group (P<0.05) and 
significantly high frequency of eNOs -786C genotype was found in CAD patients (P<0.05). The low 
levels of NO and increased frequency of T-786C polymorphism might be a risk factor in progression of 
coronary artery disease in the studied subjects. 
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Vascular Heart Disease (VHD) or coronary artery disease 
(CAD) is the major cause of mortality and morbidity in 
most countries. Among many traditional risk factors for 
CAD development, positive family history is now being 
considered as significant and novel risk factor. 
Atherosclerosis, an essential factor for the development 
of CAD, results from a defective endothelial function, 
which is ascribed mainly to an altered production of nitric 
oxide (NO), an important endothelium-derived relaxing 
factor or a vessel expansion factor (VEF) (Davignon and 
Ganz, 2004). NO is synthesized via a reaction that 
includes the conversion of L-arginine to L-citruline 
catalyzed by endothelial nitric oxide synthase (eNOS), 
which is one of the three isoforms of the enzyme 
(Angeline et al., 2010; Mayer and Hemmens, 1997). 
eNOS is the product of eNOS gene which is 21 kb in size 
and consists of 26 exons (Ragia et al., 2010; Marsden et 
al., 1993). Additionally, promoter region of the eNOS 
gene harbors several transcription factor binding sites 
and regulating gene expression (Nishevitha et al., 2009; 
Karantzoulis-Fegaras et al.,). Nitric oxide (NO) is a 
vasoactive substance and a major mediator of
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endothelium-dependent vasodilatation, which is synthe-
sized and also released in the vascular endothelium 
(Kelm, 2006; Moncada and Higgs, 1993). Nitric oxide 
diffuses from the endothelium to the vascular smooth 
muscle cells, where it increases the concentration of 
cyclic guanosine monophosphate (cGMP) by stimulating 
soluble guanyl cyclase, leading to vascular relaxation 
(Kelm, 2006; Moncada and Higgs, 1993). Nitric oxide 
(NO) is a free radical molecule that plays an essential 
role in numerous physiological actions including vaso 
regulation, inhibition of platelet aggregation and immu-
nological reactions (Gross and Wolin, 1995). 
Endothelial nitric oxide synthase (eNOS), an isoform of 
NO-producing enzymes that is fairly specific to 
endothelial cells has been found to play a prominent role 
in both angiogenesis and vasculogenesis (Kimura and 
Esumi, 2003). Recently, the eNOS gene was studied 
extensively for genetic polymorphisms to elucidate its 
genetic role in cardiovascular diseases. As a result, a 
single-nucleotide polymorphism (SNP) in the promoter 
region T-786C, was found to modify the promoter activity 
in vitro (Angeline et al., 2010; Nakayama et al., 1999). 
The eNOS is encoded by a gene (NOS3) located on 
chromosome 7q35-q36 (Esposti et al., 2011; Nadaud et 
al., 1994). A polymorphism in the 5’ flanking region of the 
NOS3 gene (T-786C) has been associated with coronary 
spasm among Japanese (Nakayama et al., 1999; Casas 
et al., 2006). It is believed that these mutations might 
result in altered NO metabolism and impaired NO 
release, leading to increased vascular tone and elevation 
in blood pressure. One of the mutations in the eNOS 
gene is a result of a thymidine (T) being replaced by a 
cytosine (C) at nucleotide -786 (T-786C). The aim of this 
present study was to determine the prevalence of T-786C 
polymorphism of eNOS in CAD patient and control. 
Because of significant effect of diabetes and smoking on 








The CAD group included 30 females and 30 males with a mean age 
of 56 years, ranging from 40 to 78 years. They had various degrees 
of stenosis in one or more of the main branch of coronary artery 
documented by coronary angiography. Patients with diabetes 
mellitus, renal disease, chronic obstructive pulmonary disease, 
hepatitis and smoker were excluded from the study group. The 
controls included 30 females and 30 males with a mean age of 54 
years, ranging from 40 to 76 years. The subjects proved to be 
healthy by health screening and had no obstructions in the coronary 





Blood samples were collected in the morning by venipuncture after  
an overnight fast and were allowed to clot at room temperature for 





1500x g for 10 min and kept at -80°C and blood samples were 
stored at -20°C until analysis. 
 
 
Measurement of serum NO 
 
The levels of NO in serum were determined colorimetrically by 
Griess method (M-Miranda et al., 2001). In this method, NO 
undergoes a series of reactions with several molecules present in 
biological fluids including O2
-
, O2 and NO2. The final products of NO 
in vivo are nitrite (NO2
-
) and nitrate (NO3
-





 varies and cannot be predicted with certainty. Thus, 





. The method used in this study provides an accurate and 
convenient measurement of nitrate/nitrite concentration in a simple 
two-step process. The first step is conversion of nitrate to nitrite 
utilizing nitrate reductase. The second step is the addition of Griess 
reagent which converts nitrite into deep purple azo compound. 
Colorimetric measurement of the absorbance due to this azo 





DNA was extracted using standard phenol-chloroform procedure. 
Genotyping of T-786C, a newly developed allele-specific 
polymerase chain reaction (PCR) was used (Figure 1) (Esposti et 
al., 2011; Little, 1995). The oligonucleotide primers used in the 
reaction are listed in Figure 1. Artificial mismatches were included in 
the 2684T and 2684C primers as indicated in Figure 1. 
Amplification was performed in a total volume of 20 µL containing 
100 ng genomic DNA, 5 µM 2684T and 2684C primers, 1.6 µM T0 
and C0 primers and 10 µL Master Mix. After a hot start at 96°C, 
amplification was achieved by 36 cycles at 94°C for 40 s, 54°C for 
40 s and 72°C for 45 s. The C and T alleles gave a 176 and a 250 





Data were analyzed with t-test, expressed as mean ± SD and x
2
 
chi-square. Data were compared in the groups by using SPSS 
software version 16. P<0.05 was chosen as the level of 
significance. Allele frequencies were calculated from the genotype 
counts. The observed genotype counts were compared with those 





RESULTS AND DISCUSSION 
 
The characteristics of the case (CAD) as well as control 
group are summarized in Table 1. VEF differences were 
noticed between the mean values of age, sex and family 
history of CAD in patient of non- smoker and control 
groups. The percent of hypertensive subject in the patient 
groups was significantly higher than that of control group 
(p<0.05) (Table 1). Comparing VEF levels in the patient 
including non-smoker and control groups, significantly 
low levels of  VEF were noticed in the patients group 
(p<0.05) (Table 2). Genotype frequencies of T-786C 
among the patient of non- smoker and control groups are 
shown in Table 3. In the present study, we found a 
marked difference in the frequency of the T-786C 
mutation of eNOS gene between patients of non- smoker 
and control groups. In total patients group, the frequency  






Figure 1. Allele specific PCR for T-786C polymorphism in the eNOS gene. Top 
panel shows the primers used in the reaction and the expected PCR products. 
Underlining in the primer sequences indicates artificially introduced mismatches. 






Figure 2. Products of PCR of T-786C polymorphism. Left, size marker 100 
bp; right, negative control (no DNA). n = 1, 2, 6: CC genotype. n = 4, 5: TT 
genotype. n = 3: TC genotype. 




Table 1. The demographic and clinical data of the patient (non- smoker) and control groups. 
 
Characteristic Patients (non-smoker) (n = 60) mean ± SD Controls (n = 60) mean ± SD P Value 
Female/male (n) 30/30 30/30 SN 
Age (years) 56 ± 6.81 54 ± 8.95 NS 
Hypertension [n (%)] 28 (46.7%) 17(28.3%) P<0.05 
Family history [n (%)] 21 (35%) 16 (26.7%) NS 
 




Table 2. The levels of VEF in patient (non-smoker) and control groups. 
 
Parameter Patients (non-smoker) (n = 60) mean ± SD Controls (n = 60) mean ± SD P Value 
VEF (µM/L) 115.08 ± 23.15 140.38 ± 42.48 P<0.05 
 




Table 3. T-786C genotype frequencies in patients (non-smoker) and control groups. 
 
Groups Genotype (TT%) Genotype (TC%) Genotype (CC%) 
Patient (non-smoker) N (%) 20 (33.3) 27 (45) 13 (21.7) 




of T/T, C/T and C/C genotypes was 33.3, 45 and 21.7%, 
respectively. In the control, the frequency of T/T, C/T and 
C/C genotypes was 65, 26.7 and 8.3%, respectively. The 
frequency of C allele was significantly higher in the 
patient group including non-smoker (p<0.05). 
Nitric oxide (NO) plays an essential role in regulating 
vascular tone and hemodynamic. NO stimulates endo-
thelial proliferation and angiogenesis, thereby playing an 
important role in wound healing and microcirculation. In 
addition, NO inhibits the release of endothelin-1 (a 
vasoconstrictor) (Angeline et al., 2010; Ignarro et al., 
1999); besides being an endothelium derived vasodilator 
molecule, NO also has important physiological and 
pathological effects. It can be synthesized in most tissue 
and cells. Its most prominent roles in cardiovascular 
system are blood pressure regulation, inhibition of throm-
bocyte aggregation, leukocyte adhesion, smooth muscle 
cell proliferation and LDL oxidation. The decrease in 
production and bioavailability are associated with events 
that accelerate development of atherosclerosis such as 
vasoconstriction, thrombocyte aggregation, migration of 
monocytes to the vascular wall, oxidized LDL and foam 
cell production. The main hypothesis of our study was 
that increased oxidative stress could reduce NO syn-
thesis. Although, patients with CAD had increased MDA 
levels, no significant correlations were determined 
between MDA and NO. NO levels were tended to be 
higher than those of the control group (Jira et al., 2011; 
Elizalde et al., 2000). NO levels showed a significant 
relation with higher BMI and hypertension in coronary 
artery disease. It was suggested that adipose tissue 
contains NO synthetase enzyme, and is thus a potential 
NO source (Jira et al., 2011; Elizalde et al., 2000). 
In a study performed with healthy individuals at 
adolescent age, it was demonstrated that serum NO 
levels highly correlated with BMI and that NO levels were 
significantly higher in obese individuals. In our study, 
serum NO levels were found significantly lower in 
patients. Scribner et al. (2003) reported that, NO levels 
are significantly lower when compared to those without 
hypertension. Again, in the same study, NO levels of the 
coronary artery patients without hypertension were 
similar to those of the control group (Scribner et al., 
2003). In this study, serum levels of NO in patient groups 
were meaningfully higher than those of the control and 
our observations confirm data from previous studies. 
Recently, several studies revealed that there are various 
mutations on eNOS gene and these mutations might be a 
risk factor for CAD. The polymorphisms differ largely 
among races. In this study, we investigated the relation-
ship between T-786C mutation of eNOS gene and CAD 
specifically in the Iranian population. To our knowledge, 
this polymorphism has never been investigated in this 
population. The results demonstrate an association 
between C allele and CAD in the Iranian population. 
The polymorphism is a result of a thymidine being 
replaced by a cytosine at nucleotide -786 (T-786C). In-
teraction between smoking eNOS genotype and CAD has 
been  reported  (Jira et al., 2011;  Hyndman et al.,  2002). 





potent suppressor of eNOS activity. Also, others found an 
association between genetic variation in the eNOS gene 
and diabetes in CAD, therefore, in this study, all subjects 
selected were non-smoker and non-diabetic. This 
polymorphism of eNOS gene was also investigated by 
several studies for the association with hypertension (Jira 
et al., 2011; Hyndman et al., 2002), the presence and 
severity of CAD (Rossi et al., 2003), and MI (Gluba et al., 
2009; Nakayama et al., 2000). Rossi et al. (2003) 
reported that they found a significant association between 
the T-786C mutation and CAD. Colombo et al. (2003) 
showed a positive association between the polymer-
phisms and the extent of CAD in the Italian population 
(Colombo et al., 2003). T-786C polymorphism was also 
reported as being related to coronary spasm in the 
Japanese by Nakayama et al. (2000) and A-Kunnas et al. 
(2002). In this study, high frequency of C/C genotype of 
T-786C was noticed in the patient group. The frequency 
of C allele was significantly higher in patient group. The 
results are in agreement with those reported by others. 
According to Nakayama et al. (1999) and Narne et al. 
(2012), the -786C allele would be associated with a 
significantly reduced ecNOS promoter activity. The 
reduced endothelial production of NO in the coronary 
arteries would predispose carriers of the C allele to 
coronary spasm. The coronary spasm might be more 
severe and prolonged in CC homozygotes, increasing the 
risk of CAD (Jaramillo et al., 2008). The T-786C mutation 
in the promoter region of eNOS resulted in the reduction 
of eNOS promoter transcription rate (Tepliakov et al., 
2010; Nakayama et al., 1999), leading to the reduced NO 
production in blood vessels and endothelial dysfunction 





It can be concluded that the presence of the eNOS 
mutant allele reduces endothelial production of NO and 
may predispose the patients carrying the mutant allele to 
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